Abeona Therapeutics shares surge 20.43% after-hours on strong Q3 earnings, Zevaskyn insurance coverage, and growing patient demand.

Abeona Therapeutics (ABEO) surged 20.43% in after-hours trading following the release of its third-quarter 2025 earnings report and business highlights. The stock’s rally was driven by strong operational updates, including the optimization of the FDA-mandated sterility assay for Zevaskyn, allowing the resumption of patient biopsies and treatment anticipation in Q4 2025. The company reported robust patient demand, with 30 eligible patients identified across three activated treatment centers and coverage secured by all major commercial payers, including UnitedHealthcare and Aetna. Additionally, Abeona highlighted $207.5 million in cash reserves, sufficient to fund operations for over two years, and strategic expansion of its gene therapy pipeline, including selection for the FDA’s Rare Disease Endpoint Advancement program. These developments reinforced confidence in the commercial viability of Zevaskyn and long-term growth prospects, despite a temporary delay in initial treatments.